Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

162 results
Display

Diagnostic Performance of Serum Asialo-α1-acid Glycoprotein for Advanced Liver Fibrosis or Cirrhosis in Patients with Chronic Hepatitis B or Nonalcoholic Fatty Liver Disease

Kim SU, Jeon MY, Lim TS

BACKGROUND/AIMS: The utility of asialo-α1-acid glycoprotein (AsAGP) for assessing the fibrotic burden is unknown. This study examined the diagnostic performance of the AsAGP level for advanced liver fibrosis or cirrhosis...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Risk assessment of hepatocellular carcinoma development for indeterminate hepatic nodules in patients with chronic hepatitis B

Shin H, Jung YW, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Kim YY, Choi JY, Kim SU

BACKGROUND/AIMS: A risk prediction model for the development of hepatocellular carcinoma (HCC) from indeterminate nodules detected on computed tomography (CT) (Rad(CT) score) in patients with chronic hepatitis B (CHB)-related cirrhosis...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effect of Statin Use on Liver Cancer Mortality Considering Hypercholesterolemia and Obesity in Patients with Non-Cirrhotic Chronic Hepatitis B

Kim GA, Shim JJ, Lee JS, Kim BH, Kim JW, Oh CH, Oh CM, Oh IH, Park SY

Little is known about the benefits of statin use on liver cancer mortality among patients with chronic hepatitis B (CHB) considering hypercholesterolemia and obesity. A nationwide retrospective cohort study was...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
New Biomarkers of Chronic Hepatitis B

Mak LY, Seto WK, Fung J, Yuen MF

Chronic hepatitis B (CHB) infection leads to clinically heterogeneous disease outcomes. Different viral markers are utilized to monitor treatment effects and predict risk of complications in patients with CHB. Hepatitis...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
New Potential Therapies for Chronic Hepatitis B

Yoo SH, Kwon JH

A HBV infection is a dynamic disease and long-term liver inflammation contributes to the development of liver cirrhosis and hepatocellular carcinoma. Currently available nucleos(t)ide analogues and pegylated interferon are effective...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Prophylactic Antiviral Treatment in Immunosuppressed Chronic Hepatitis B Patients

Yoon EL

Improved management of chronic hepatitis B patients with oral nucleos(t)ide analogues has increased the number of these patients who are getting older and have other accompanying comorbidities. These comorbidities frequently...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Natural History and Treatment Indications of Chronic Hepatitis B

Sinn DH

HBV is the most common etiology of both liver cirrhosis and hepatocellular carcinoma in Korea. Despite much progress made, the currently available antiviral therapies cannot eradicate or eliminate this virus....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Patchy echogenicity of the liver in patients with chronic hepatitis B does not indicate poorer elasticity

Wu S, Tu R, Liang X

PURPOSE: This study was conducted to investigate whether the presence of patchy echogenicity in the liver of patients with chronic hepatitis B (CHB) is predictive of liver stiffness. METHODS: A total...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Result Patterns and Characteristics of HBeAg and HBV DNA in Patients with Chronic Hepatitis B

Choi EJ, Kim JH, Han MS

BACKGROUND: Discrepancies in the results between hepatitis B e-antigen (HBeAg) and hepatitis B virus (HBV) DNA levels pose difficulties in the management of chronic hepatitis B (CHB). This study aims...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir

Kim DS, Jeon MY, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Kim SU

BACKGROUND/AIMS: The influence of hepatic steatosis (HS) on chronic hepatitis B (CHB) is unclear. We evaluated the influence of the degree of HS, assessed using the controlled attenuation parameter (CAP)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
How does hepatic steatosis affect the outcome of patients with chronic hepatitis B?

Yu JH, Lee JW

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy of long-term tenofovir disoproxil fumarate therapy in chronic hepatitis B patients with partial virologic response in real practice

Song JE, Lee CH, Kim BS

BACKGROUND/AIMS: The optimal management of chronic hepatitis B (CHB) patients with partial virologic response (PVR) to tenofovir disoproxil fumarate (TDF) remains unclear. We aimed to evaluate the long-term efficacy of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Are the Patients in the Immune Tolerant Phase of Chronic Hepatitis B far from Hepatocellular Carcinoma or Death?

Heo NY

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Evaluation of Noninvasive Liver Fibrosis Blood Markers in Patients with Chronic Hepatitis B and Hepatitis C

Lee JH, Cho J, Kim J, Uh Y, Youn KJ

BACKGROUND: Liver fibrosis evaluation is an important issue in chronic liver disease patients. We aimed to develop noninvasive liver fibrosis biomarkers based on transient elastography (TE, FibroScan®) through retrospective review...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Unmet need in chronic hepatitis B management

Liang LY, Wong GL

Despite all these exciting developments, there remain some unmet needs in the management for patients with chronic hepatitis B (CHB). As majority of CHB patients are going to use oral...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
KASL clinical practice guidelines for management of chronic hepatitis B

Korean Association for the Study of the Liver (KASL)

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Updated Treatment of Chronic Hepatitis B

Yoon EL, Yim HJ

Chronic hepatitis B virus (HBV) infection is a major cause of liver cirrhosis and hepatocellular carcinoma in Korea. The prevalence of HBV infection is gradually decreasing in Korea, but 3.0%...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B

Lee YB, Ha Y, Chon YE, Kim MN, Lee JH, Park H, Kim KI, Kim SH, Rim KS, Hwang SG

BACKGROUND/AIMS: Nonalcoholic fatty liver disease (NAFLD) is becoming a worldwide epidemic, and is frequently found in patients with chronic hepatitis B (CHB). We investigated the impact of histologically proven hepatic...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
2018 Korean Association for the Study of the Liver (KASL) Clinical Practice Guidelines of Chronic Hepatitis B: What's Different?

Kim JH

The clinical practice guideline for the management of chronic hepatitis B (CHB) was originally enacted in 2004 by the Korean Association for the Study of the Liver in order to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Treatment Outcome and Renal Safety of 3-Year Tenofovir Disoproxil Fumarate Therapy in Chronic Hepatitis B Patients with Preserved Glomerular Filtration Rate

Min IS, Lee CH, Shin IS, Lee NE, Son HS, Kim SB, Seo SY, Kim SH, Kim SW, Lee SO, Lee ST, Kim IH

BACKGROUND/AIMS: To investigate the treatment efficacy and renal safety of long-term tenofovir disoproxil fumarate (TDF) therapy in chronic hepatitis B (CHB) patients with preserved renal function. METHODS: The medical records of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr